HKU Scholars Hub: Browsing DSpace

Browsing by Author Brainard, DM

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 8 of 8

	Title	Author(s)	Issue Date
	Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection Journal:Journal of Viral Hepatitis	Asselah, T Shafran, SD Bourgeois, S Lai, CL Mathurin, P Willems, B Nguyen, MH Davis, MN Huang, KC Svarovskaia, E Osinusi, A McNally, J Brainard, DM Shaikh, OS Tran, TT	2019
	Integrated analysis of controlled clinical trials evaluating efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C genotype 6 (HCV GT 6) Proceeding/Conference:Journal of Hepatology	Nguyen, MH Chuang, WL Hassanein, T Kowdley, K Lai, CL Chan, HLY Feld, JJ Letterio, C Hahambis, TA Llewellyn, J De-Oertel, S Brainard, DM Lawitz, EJ Gane, EJ	2017
	Sofosbuvir and Ledipasvir/Sofosbuvir for the treatment of patients with Chronic Genotype 6 Hepatitis C Virus Infection: integrated analysis of Phase 2 and Phase 3 studies Proceeding/Conference:Hepatology	Gane, EJ Chuang, WL Hassanein, TI Kowdley, KV Lawitz, E Gao, B Mo, H Hyland, RH Yang, JC De-Oertel, S Brainard, DM Knox, SJ McHutchison, JG Lai, CL Chan, HLY	2015
	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Journal:New England Journal of Medicine	Feld, JJ Jacobson, IM Hézode, C Asselah, T Ruane, PJ Gruener, N Abergel, A Mangia, A Lai, CL Chan, HLY Mazzotta, F Moreno, C Yoshida, E Shafran, SD Towner, WJ Tran, TT McNally, J Osinusi, A Svarovskaia, E Zhu, Y Brainard, DM McHutchison, JG Agarwal, K Zeuzem, S	2015
	Sofosbuvir plus ribavirin for 12 16 or 24 weeks results in sustained virologic response over 97% in genotype 1 and 6 HCV infection in Hong Kong Proceeding/Conference:Hepatology International	Lai, CL Yuen, MF Yang, JC Knox, SJ Mo, HM Han, LL Brainard, DM Mchutchison, JG Wong, VWS Chan, HLY	2015
	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong Journal:Alimentary Pharmacology & Therapeutics	Lai, CL Wong, VWS Yuen, RMF Yang, JC Knox, SJ Mo, H Han, LL Brainard, DM Chan, HLY	2016
	Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study Proceeding/Conference:Hepatology International	Chan, HLY Feld, JJ Agarwal, K Hezode, C Asselah, T Ruane, PJ Gruener, N Abergel, A Mangia, A Lai, CL Mazzotta, F Moreno, C Yoshida, E Shafran, SD Towner, WJ Tran, TT McNally, J Brainard, DM Jacobson, IM Zeuzem, S	2016
	Sofosbuvir/velpatasvir for 12 weeks results in high SVR12 rates with a favorable safety profile in asian patients: an integrated subgroup analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies Proceeding/Conference:Hepatology International	Chan, HLY Lai, CL Feld, J Reau, N Han, L McNabb, BL McNally, J Brainard, DM Foster, G Roberts, S	2017

Showing results 1 to 8 of 8